Literature DB >> 2143439

In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines.

M Sykes1, K A Hoyles, M L Romick, D H Sachs.   

Abstract

The development of methods of avoiding graft-versus-host disease (GVHD) while retaining the alloengraftment-promoting and anti-leukemic effects of allogeneic T cells is a major goal of research in bone marrow transplantation (BMT). We have recently obtained evidence suggesting that natural suppressor (NS) cells derived from T cell-depleted (TCD) syngeneic marrow can protect against GVHD while permitting alloengraftment. We have now attempted to enrich and then propagate NS cells in vitro, with the goal of obtaining an enhanced anti-GVHD effect by adoptive transfer in vivo. Two long-term cell lines were generated culturing BMC depleted of Mac1-positive cells and of Mac1-positive plus Thy1-positive cells in high concentrations of IL-2. Both cell lines showed anti-GVHD effects when administered along with a GVHD-producing inoculum, while permitting complete allogeneic reconstitution. A clone derived from Mac1-depleted BMC protected completely against a more chronic pattern of GVHD. These cell lines demonstrated suppressive activity in vitro, cytolytic activity against a broad range of natural killer (NK)-sensitive and NK-resistant targets, and a novel cell surface phenotype, with characteristics of both alpha beta-TcR-bearing T cells and of NK cells. In some respects, these cells resemble LAK cells and differ from fresh NS cells, and from the cloned NS cells derived from spleens of total lymphoid irradiation (TLI)-treated mice and neonatal mice. To our knowledge, this is the first detailed phenotypic analysis of cell lines with in vivo anti-GVHD activity. If applicability can be demonstrated in large animal models, the ability to use bone marrow as a source of such protective cell lines might also have potential utility in clinical BMT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143439     DOI: 10.1016/0008-8749(90)90222-d

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

Review 1.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

2.  New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses.

Authors:  Dong Zhang; Wei Yang; Nicolas Degauque; Yan Tian; Allison Mikita; Xin Xiao Zheng
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

3.  Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.

Authors:  Angela Shaulov; Simon Yue; Ruojie Wang; Robin M Joyce; Steven P Balk; Haesook T Kim; David E Avigan; Lynne Uhl; Robert Sackstein; Mark A Exley
Journal:  Exp Hematol       Date:  2008-02-08       Impact factor: 3.084

Review 4.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

5.  Similar rates of production of T and B lymphocytes in the bone marrow.

Authors:  S Dejbakhsh-Jones; H Okazaki; S Strober
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

6.  Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.

Authors:  D Zeng; D Lewis; S Dejbakhsh-Jones; F Lan; M García-Ojeda; R Sibley; S Strober
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

Review 7.  Double Negative T Regulatory Cells: An Emerging Paradigm Shift in Reproductive Immune Tolerance?

Authors:  Enitome E Bafor; Julio C Valencia; Howard A Young
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 8.  Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease.

Authors:  Ramzi Abboud; Jaebok Choi; Peter Ruminski; Mark A Schroeder; Sena Kim; Camille N Abboud; John F DiPersio
Journal:  Ther Adv Hematol       Date:  2020-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.